✦ LIBER ✦

Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid

✍ Scribed by Chiara Pilatrino; Daniela Cilloni; Emanuela Messa; Alessandro Morotti; Emilia Giugliano; Marisa Pautasso; Ubaldo Familiari; Susanna Cappia; Pier Giuseppe Pelicci; Francesco Lo Coco; Giuseppe Saglio; Angelo Guerrasio

Book ID: 102804444
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 772 KB
Volume: 104
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21132

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical trial of valproic acid and all-

Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia

✍ Gesine Bug; Markus Ritter; Barbara Wassmann; Claudia Schoch; Thorsten Heinzel; K 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 275 KB 👁 2 views

## Abstract ## BACKGROUND Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, induced in vitro differentiation of primary acute myeloid leukemia (AML) blasts, an effect enhanced by all‐trans retinoic acid (ATRA). Clinical responses to VPA were recently observed in patients with myelodyspl

The histone deacetylase (HDAC) inhibitor

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia

✍ Andrea Kuendgen; Mathias Schmid; Richard Schlenk; Sabine Knipp; Barbara Hildebra 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB 👁 2 views

## Abstract ## BACKGROUND Valproic acid (VPA) inhibits histone deacetylase activity and, synergizing with all‐trans retinoic acid (ATRA), achieves differentiation induction of myeloid blast cells in vitro. ## METHODS We used VPA in 58 patients with acute myeloid leukemia (AML) who were too old a

Acute myelogenous leukemia in a patient

Acute myelogenous leukemia in a patient with Li–Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report

✍ Ånensen, N; Skavland, J; Stapnes, C; Ryningen, A; Børresen-Dale, A-L; Gjertsen, 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 119 KB

Phase III study of all-trans retinoic ac

Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia

✍ Waterhouse, C; Schoch, R; Schlenk, R F; Fröhling, S; Hartmann, F; Fischer, J Th; 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 130 KB

Results of a phase 2 study of valproic a

Results of a phase 2 study of valproic acid alone or in combination with all-transretinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia

✍ Andrea Kuendgen; Sabine Knipp; Frank Fox; Corinna Strupp; Barbara Hildebrandt; C 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 97 KB

A subset of patients with high-risk acut

A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid

✍ Anita Ryningen; Camilla Stapnes; Philippe Lassalle; Matthias Corbascio; Bjørn-To 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 662 KB